See article, p. 234.

Understanding the impact of cancer and cancer therapies on susceptibility to severe COVID-19 is critical to optimize treatments for these patients. This study documents real-world experience of clinical care for multiple myeloma patients with SARS-CoV-2, with clinical and demographic factors associated with severity of the infection outcomes. Anti-myeloma therapies did not show a detectable influence on COVID-19 outcomes. These findings provide groundwork to understanding vulnerabilities of patients with blood malignancies to COVID-19.

See article, p. 244.

Diagnostic classification of cancer subtypes based on gene expression signatures has improved outcome prediction and optimal treatment selection. It is increasingly used to evaluate aggressive lymphoma subtypes. However, training and testing datasets require normalization across batches, technological platforms, and processing pipelines, reducing the accuracy. To overcome this limitation, Ryan Morin and colleagues developed an algorithm PRPS-ST (probability ratio-based classification prediction score), which self-trains on a dataset regardless of...

You do not currently have access to this content.